tiprankstipranks
Holding GB:CBIO?
Track your performance easily

GB:CBIO Holdings Information

CBIO has a total of 32 holdings. The top 10 holdings account for 60.63%.
Holdings Count
32
Total Assets
1.03M
Top 10 Percentage
60.63%
Asset Class
Equity
Category
Size And Style
Region
Asia-Pacific
See the full list of holdings, find out what stocks are the most undervalued and get access to the all ETF's smart score and filters.Go Premium
32 Holdings as of Jul 19, 2024
Name
Weight %
Market Value
Price & Change
Market Cap
Yearly Gain
Analyst Consensus
Analyst Price Target
Smart Score
Follow
600276
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A
9.10%
$93.35K
premium
603259
WuXi AppTec Co., Ltd. Class A
9.07%
$92.97K
premium
Innovent Biologics
8.88%
$91.05K
$8.45B
16.74%
5 Buy
0 Hold
0 Sell
Strong Buy
premium
Wuxi Biologics (Cayman)
7.14%
$73.18K
$5.75B
-73.51%
2 Buy
1 Hold
0 Sell
Moderate Buy
premium
002252
Shanghai RAAS Blood Products Co., Ltd. Class A
6.48%
$66.41K
premium
Sino Biopharmaceutical
4.78%
$48.97K
$6.68B
-27.08%
2 Buy
0 Hold
0 Sell
Moderate Buy
premium
600161
Beijing Tiantan Biological Products Corporation Limited Class A
4.68%
$48.00K
premium
Akeso, Inc.
3.76%
$38.52K
HK$34.85B
4.41%
5 Buy
1 Hold
0 Sell
Strong Buy
premium
300573
Shenyang Xingqi Pharmaceutical Co., Ltd. Class A
3.40%
$34.85K
premium
Hansoh Pharmaceutical Group Company Limited
3.35%
$34.31K
HK$102.57B
40.37%
1 Buy
0 Hold
0 Sell
Moderate Buy
premium

CBIO ETF FAQ

What are ETF GB:CBIO’s top 3 holdings?
GB:CBIO’s top 3 holdings are CN:600276, CN:603259, HK:1801.
    What is ETF GB:CBIO’s holdings count?
    ETF GB:CBIO’s is holdings 32 different assets.
      What are the total assets of ETF GB:CBIO?
      ETF GB:CBIO’s total assets are 1.03M.
        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis